BET inhibitors in combination with γ-secretase inhibitors for T cell acute lymphoblastic leukemia and BRAF-inhibitor (vemurafenib) for BRAF-inhibitor...

stage. Small molecule inhibitors of non-BET bromodomain proteins BRD7 and BRD9 have also been developed. Chromodomain BET inhibitor BRD2 BRD3 BRD4 BRD7...

CPI-0610 is a drug which acts as a BET inhibitor, mainly acting at the BRD2 and BRD4 subtypes. It has potential applications in the treatment of various...

inhibitor of the BET family of bromodomain proteins which include BRD2, BRD3, BRD4, and the testis-specific protein BRDT in mammals. BET inhibitors structurally...

morpholine-containing chemical compound that is a potent inhibitor of numerous proteins, and a strong inhibitor of phosphoinositide 3-kinases (PI3Ks). It is generally...

in clinical trials. Overall, there is a mean survival of 6–9 months. BET inhibitor RESERVED, INSERM US14-- ALL RIGHTS. "Orphanet: NUT midline carcinoma"...

able to prevent successful interaction between BET proteins and acetylated histones. Using a BET inhibitor can reduce the over expression of bromodomain...

R. Herrman, B. Merkely, M. Borgman, S.E. Nissen. Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of...

(MUFJ) keiretsu. Mitsubishi-Tanabe Pharmaceuticals developed the first BET inhibitor molecules. In August 2014, the company announced three-year research...

rearrangements (i.e. DH/THL). RO6870810, another BET inhibitor, in combination with Venetoclax, an inhibitor of the Bcl-2 protein, is likewise in a phase...